Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2017
SIETES contiene 92005 citas

 
 
 1 a 20 de 884 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med 2017;177:1308-15. [Ref.ID 102042]
2. Cita con resumen
Ebell MH. WHO downgrades status of oseltamivir. BMJ 2017;358:j3266. [Ref.ID 101981]
3. Cita con resumen
Kuoppala J, Enlund H, Pulkkinen J, Kastarinen H, Jyrkkä J, Happonen P, Paajanen H. ACE inhibitors and the risk of acute pancreatitis — A population-based case–control study. Pharmacoepidemiol Drug Saf 2017;26:853-7. [Ref.ID 101965]
4. Cita con resumen
Wei L, Ratnayake L, Phillips G, McGuigan CC, Morant SV, Flynn RW, Mackenzie IS, MacDonald TM. Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study. Br J Clin Pharmacol 2017;83:1298-308. [Ref.ID 101942]
5. Cita con resumen
Li L, Geraghty OC, Mehta Z, Rotwell PM, on behalf of the Oxford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 2017;390:490-9. [Ref.ID 101638]
6.Tiene citas relacionadas Cita con resumen
Grosser T. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2017;376:1389-90. [Ref.ID 101526]
7.
Felson DT. Safety of nonsteroidal antiinflammatory drugs.. N Engl J Med 2016;373:2595-6. [Ref.ID 101348]
8. Cita con resumen
Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess 2016;20:1-406. [Ref.ID 101044]
9. Cita con resumen
Anónimo. Celecoxib safety revisited. The Medical Letter on Drug and Therapeutics Bulletin 2016;58:159. [Ref.ID 101041]
10.Tiene citas relacionadas Cita con resumen
Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckeman B, Berger MF, Bao W, Lincoff AM, for the PRECISION Trial Investigators. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016;373:2519-29. [Ref.ID 101038]
11.Enlace a cita original Cita con resumen
Patrono C. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. Br J Clin Pharmacol 2016;82:957-64. [Ref.ID 100827]
12. Cita con resumen
Hemkens LG, Ewald H, Briel M. Colchicine and prevention of cardiovascular events. JAMA 2016;316:1106-007. [Ref.ID 100745]
13. Cita con resumen
Hemkens LG, Ewald H, Briel M. Colchicine and prevention of cardiovascular events. JAMA 2016;316:1106-7. [Ref.ID 100660]
14.Tiene citas relacionadas Cita con resumen
Faillie J-L, Yu OH, Hillaire-Buys D, Barkun A, Azoulay L. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Intern Med 2016;176:1 de octubre. [Ref.ID 100559]
15.Tiene citas relacionadas Cita con resumen
Azoulay L, Filion KB, Platt RW, Dormuth CR, Clemens KK, Durand M, Hu N, Juurlink DN, Paterson JM, Targownik LE, Turin TC, Ernst P, and the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Association between incretin-based drugs and the risk of acute pancreatitis . JAMA Intern Med 2016:1 de octubre. [Ref.ID 100558]
16. Cita con resumen
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, for the LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:28 de julio. [Ref.ID 100511]
18. Cita con resumen
Wise J. NICE approves immunotherapy combination for advanced melanoma. BMJ 2016;353:i3421. [Ref.ID 100435]
19.Tiene citas relacionadas Cita con resumen
Messerli FH, Bangalore S, Grossman E. Adverse effects and tolerability of ß blockers. BMJ 2016;353:i3142. [Ref.ID 100378]
20. Cita con resumen
Kuehn BM. FDA's foray into big data still maturing. JAMA 2016;315:1934-6. [Ref.ID 100291]
Seleccionar todas
 
 1 a 20 de 884 siguiente >>